l

Request a Quote

Discovery &
Rapid PoC

Learn More

ADC Services

Bioconjugation

Payloads & Linkers

Targeted Protein Degraders

Advanced
Chemistry

Learn More

Medicinal Chemistry

Payloads & Linkers

Custom Synthesis

Translational
Research

Learn More

CDX

Immuno-Oncology Studies

Humanized Mouse Model

PDX

PK/PD Studies

in vitro Studies

IND Support

Spheroids & Organoids

Analytical
& QC

Learn More

ADCs & Other Large Molecules

mRNA Characterization

Small Molecules

GMP Method Validation Process

GMP
Manufacturing

Learn More

ADCs

Bioconjugation

Payloads & Linkers

mRNA

Antibody-Oligonucleotide Conjugates

Flexible Business
Models

Learn More

FFS

FTE

Milestone-Based

Blended FTE

LARGE MOLECULES & mRNA DEVELOPMENT

CDX (Human Cell Line Xenograft)

Bioconjugation

Advanced conjugation of proteins with diverse linkers and payloads using multiple technologies

VISIT PAGE >

Immuno-Oncology models

mRNA

End-to-end custom mRNA synthesis from early research to scalable production

VISIT PAGE >

Humanized Immune Mouse model

Antibody Production

Rapid generation of standard and engineered monoclonal antibodies using transient cell lines

VISIT PAGE >

TESTING & CHARACTERIZATION

CDX (Human Cell Line Xenograft)

Translational Research

Comprehensive in vitro and in vivo studies to assess efficacy and reduce early-stage risk

VISIT PAGE >

Immuno-Oncology models

Analytical Services

Method development, validation, stability testing, and structural characterization

VISIT PAGE >

Humanized Immune Mouse model

Bioanalytical Services

PK/PD analysis and biomolecule characterization using LC-MS, ELISA, and assays

VISIT PAGE >

Humanized Immune Mouse model

Functional Assays

Custom assay development for mechanistic and functional insights

VISIT PAGE >

Humanized Immune Mouse model

BioNMR

High-resolution structural analysis of biomolecules and complexes using BioNMR

VISIT PAGE >

MOLECULE DESIGN & SYNTHESIS

CDX (Human Cell Line Xenograft)

Payloads & Linkers

Design and GMP manufacturing of high-potency payloads and linkers

VISIT PAGE >

Immuno-Oncology models

Medicinal Chemistry

Hit-to-lead optimization and custom synthesis with translational support

VISIT PAGE >

Humanized Immune Mouse model

Antibody Production

Synthesis and purification of modified oligonucleotides for research and clinical use

VISIT PAGE >

Humanized Immune Mouse model

Nucleotides

Development of specialized nucleotide building blocks and modified chemistries

VISIT PAGE >

Humanized Immune Mouse model

Protein Degraders

Synthetic chemistry, linker design and analytical capabilities for protein degraders

VISIT PAGE >

Humanized Immune Mouse model

Custom Synthesis

Troubleshooting, route design, and process optimization for complex molecules

VISIT PAGE >

GMP Manufacturing (Phase 1 & Phase 2)

Comprehensive GMP manufacturing capabilities spanning process development, drug substance (DS) production, analytical support, and quality for Phase 1 and Phase 2 clinical trials

FTE Arrangement

Flexible, scalable FTE support tailored for cost efficiency and complex project needs

Testimonials

“NJ Bio was challenged to synthesize novel phosphoramidites at the gram scale for our company. The team quickly divided up the task and probed which synthetic route would be scalable. With minor tweaks to each phosphoramidite, the team completed each target in a time frame that matched our needs perfectly. A variety of characterization was supplied including phosphorus NMR, and 2D homonuclear spectra. We would trust further projects to be carried out by NJ Bio in the future to be of similar quality and timeliness.”
Director
Large US-based Biotech Company
☆☆☆☆☆
“NJ Bio was challenged to synthesize novel phosphoramidites at the gram scale for our company. The team quickly divided up the task and probed which synthetic route would be scalable. With minor tweaks to each phosphoramidite, the team completed each target in a time frame that matched our needs perfectly. A variety of characterization was supplied including phosphorus NMR, and 2D homonuclear spectra. We would trust further projects to be carried out by NJ Bio in the future to be of similar quality and timeliness.”
Director, Large US-based Biotech Company
Director
Large US-based Biotech Company
“I want to send you this testimonial in support of working with NJ Bio as our main ADC CRO. Over the last 20 years of ADC work, I have worked with a large number of different CROs in the ADC field. By far, NJ Bio has been the easiest to work with, and the highest quality materials have been produced by their scientists to support our programs. The scientific team at NJ Bio is top tier, and we trust them with our most precious programs. They have successfully produced extremely complicated custom compounds for us, and in impressive turn-around times. Of all the CROs that we work with, we consider NJ Bio to be our main strategic partner and actually have factored our business relationship with them into our future growth plans.”
Director, Process Development & Technical Transfer
ADC Platform Company
☆☆☆☆☆
“I want to send you this testimonial in support of working with NJ Bio as our main ADC CRO. Over the last 20 years of ADC work, I have worked with a large number of different CROs in the ADC field. By far, NJ Bio has been the easiest to work with, and the highest quality materials have been produced by their scientists to support our programs. The scientific team at NJ Bio is top tier, and we trust them with our most precious programs. They have successfully produced extremely complicated custom compounds for us, and in impressive turn-around times. Of all the CROs that we work with, we consider NJ Bio to be our main strategic partner and actually have factored our business relationship with them into our future growth plans.”
Director, Process Development & Technical Transfer, ADC Platform Company
Director, Process Development & Technical Transfer
ADC Platform Company
“We have worked with a number of CROs in the past, but feel we have found an ideal, long-term partner with NJ Bio for our antibody drug conjugate activities. NJ Bio has been open to accommodate changes beyond agreed scope to improve quality or adapting to different needs. The expert team at NJ Bio is highly competent and the project progress was presented and discussed on a regular basis to achieve our goals on time.”
Director of Antibody Research
European-based Company
☆☆☆☆☆
“We have worked with a number of CROs in the past, but feel we have found an ideal, long-term partner with NJ Bio for our antibody drug conjugate activities. NJ Bio has been open to accommodate changes beyond agreed scope to improve quality or adapting to different needs. The expert team at NJ Bio is highly competent and the project progress was presented and discussed on a regular basis to achieve our goals on time.”
Director of Antibody Research, European-based Company
Director of Antibody Research
European-based Company
“When we were looking for a CRO with expertise in the ADC field and one that could work closely with an early-stage company, NJ Bio stepped up to the plate to help. They were able to meet our timelines, provide valuable insight, and deliver several quality ADCs to evaluate in our in vitro and in vivo studies. We will continue to utilize NJ Bio’s services as our internal ADC program continues to mature.”
Founder and CEO
Early Stage Biotech Company
☆☆☆☆☆
“When we were looking for a CRO with expertise in the ADC field and one that could work closely with an early-stage company, NJ Bio stepped up to the plate to help. They were able to meet our timelines, provide valuable insight, and deliver several quality ADCs to evaluate in our in vitro and in vivo studies. We will continue to utilize NJ Bio’s services as our internal ADC program continues to mature.”
Founder and CEO, Early Stage Biotech Company
Founder and CEO
Early Stage Biotech Company
“Great people, excellent chemistry, strong collaboration and exceptional execution ”
Midsize Biopharmaceutical Company
☆☆☆☆☆
“Great people, excellent chemistry, strong collaboration and exceptional execution”
Midsize Biopharmaceutical Company
Midsize Biopharmaceutical Company
“Thanks to the entire NJ Bio team for helping us review and release the Drug-Linker on time!!! It took a well-coordinated and executed plan to make this happen. QA was able to release the material in record time which was only possible with the NJ Bio team’s support in record review and rapid testing and release on their end. It has been a pleasure working with the team and I look forward to our work in 2026.”
Executive Operations QA Director
Clinical Quality Assurance, Midsize Biopharmaceutical Company
☆☆☆☆☆
“Thanks to the entire NJ Bio team for helping us review and release the Drug-Linker on time!!! It took a well-coordinated and executed plan to make this happen. QA was able to release the material in record time which was only possible with the NJ Bio team’s support in record review and rapid testing and release on their end. It has been a pleasure working with the team and I look forward to our work in 2026.”
Executive Operations QA Director
Executive Operations QA Director
Clinical Quality Assurance, Midsize Biopharmaceutical Company

NJ Bio, Inc. and Ajinomoto Bio-Pharma Services Partner to Advance ADC and AOC Development

When Chemistry Became the Difference: Our Path from R&D to GMP Manufacturing

When Chemistry Became the Difference: Our Path from R&D to GMP Manufacturing

NJ Bio to Present in Asia at Two Major Conferences in 2026

NJ Bio recognized by long-standing client Exelixis for outstanding service in 2025

NJ Bio recognized by long-standing client Exelixis for outstanding service in 2025

NJ Bio Advances ADC Structural Analysis with First Published 2D NMR Spectra

NJ Bio Named Runner-Up for Best CRO at the 12th Annual World ADC Awards

NJ Bio Named Runner-Up for Best CRO at the 12th Annual World ADC Awards

NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P® Services

Cohance Lifesciences Announces USD 10 mn Investment in cGMP Bioconjugation Suite at NJ Bio, Princeton, NJ, U.S. to Accelerate ADC Innovation

NJ Bio, Inc., and Sapala to Participate in TIDES Europe 2025 in Basel, Switzerland

ADC Losses Top $13.4 Billion in Biotech Sector

NJ Bio - Excellence in ADC CRO Services

Latest News

Resources

Recent Advances in ADCs

Payload Classes for ADCs

Linkers for ADCs

Targeted Protein Degraders

BioNMR for Drug Discovery

Compliance & Accreditations